Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass.--()--Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that a poster presentation that includes updated results from the ongoing Phase 1 clinical study of DCC-2618, the company’s pan-KIT and PDGFRα inhibitor, will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 - 6, 2017, in Chicago IL. Details of the presentation are as follows:

Poster Title: Pharmacokinetic-driven phase 1 study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients with gastrointestinal stromal tumor (GIST) and other solid tumors.
Author: Filip Janku, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
Session: Poster Discussion Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Abstract #: 2515
Date and Time: Monday, June 5, 2017, 8:00 AM – 11:30AM (CST)
Poster Discussion Session: Monday, June 5, 2017 11:30 AM-12:45 PM (CST)

“We are very pleased to present these important results and to provide an update on the clinical development of DCC-2618, our pan-KIT and PDGFRα inhibitor in development for difficult to treat, KIT and/or PDGFRα-driven cancers with limited therapeutic options,” said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer.

“These maturing data confirm earlier results presented at the 2016 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,” added Oliver Rosen, M.D., Deciphera’s Chief Medical Officer. “The encouraging clinical activity achieved in patients with a broad spectrum of mutations and prior therapies in our Phase 1 study supports the impressive translational data presented last month at the 2017 American Association for Cancer Research (AACR) Annual Meeting”.

About DCC-2618
DCC-2618 is currently in a first-in-human Phase 1 clinical trial. DCC-2618 is a pan-KIT and PDGFRα kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis.

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off’ or inactivated conformation. These therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their response to treatment.

Contacts

Deciphera Pharmaceuticals, LLC
Christopher J. Morl, 781-209-6418
Chief Business Officer
cmorl@deciphera.com
or
Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com

Release Summary

A poster presenting updated results from the ongoing Phase 1 clinical study of DCC-2618 will be presented at the 2017 American Society of Clinical Oncology (ASCO)

Contacts

Deciphera Pharmaceuticals, LLC
Christopher J. Morl, 781-209-6418
Chief Business Officer
cmorl@deciphera.com
or
Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com